---
ID: 3179
post_title: >
  Sanofi confident it can win Medivation
  shareholder support
author: Staff Writer
post_date: 2016-04-29 09:06:11
post_excerpt: ""
layout: post
permalink: >
  https://www.whenitson.com/sanofi-confident-it-can-win-medivation-shareholder-support/
published: true
original_cats:
  - topNews
original_title:
  - >
    Sanofi confident it can win Medivation
    shareholder support
original_link:
  - >
    http://feeds.reuters.com/~r/reuters/topNews/~3/DxudX35DKoY/us-sanofi-results-idUSKCN0XQ0C8
canonical_url:
  - >
    http://feeds.reuters.com/~r/reuters/topNews/~3/DxudX35DKoY/us-sanofi-results-idUSKCN0XQ0C8
---
 [ad_1]
<br><div id="articleText">
<span id="midArticle_start"/>

<span id="midArticle_0"/><span class="focusParagraph" readability="6"><p><span class="articleLocation">PARIS</span> Sanofi (<span id="symbol_SASY.PA_0">SASY.PA</span>), which reported higher quarterly profit on Friday boosted by its Genzyme division, is confident Medivation (<span id="symbol_MDVN.O_1">MDVN.O</span>) shareholders will back its proposed takeover of the U.S. cancer drug company.</p></span><span id="midArticle_1"/><p>The French drugmaker went public on Thursday with a $9.3 billion offer to buy Medivation after it stonewalled its takeover approach, setting up what could be a lengthy battle.</p><span id="midArticle_2"/><p>"We are confident that Medivation shareholders will ultimately share our strong belief that our offer ... would provide significant and immediate cash value," Sanofi Chief Executive Olivier Brandicourt said on a conference call.</p><span id="midArticle_3"/><p>Chief Financial Officer Jerome Contamine declined to say whether Sanofi was ready to engage in a bidding war.</p><span id="midArticle_4"/><p>Medivation, which markets prostate cancer drug Xtandi, said in a statement that its board would meet to discuss Sanofi's proposal and provide an update "promptly" but added that there was no guarantee a deal would be reached.</p><span id="midArticle_5"/>
        
        <span class="first-article-divide"/><p>The U.S. company said shareholders should take no action at this time.</p><span id="midArticle_6"/><p>Shares in Sanofi were down 2.32 percent at 0743 GMT.</p><span id="midArticle_7"/><p>Sanofi said first-quarter business net profit grew 3.5 percent at constant exchange rates to 1.72 billion euros ($1.96 billion), equivalent to a 0.2 percent drop on a reported basis.</p><span id="midArticle_8"/>
        
        <span class="second-article-divide"/><p>Sales rose 0.7 percent at constant exchange rates to 8.54 billion euros, down 1.9 percent on a reported basis, Sanofi said, adding that it was confirming its full-year forecasts.</p><span id="midArticle_9"/><p>Analysts polled by Reuters had on average expected business net profit of 1.7 billion euros and net sales of 8.73 billion.</p><span id="midArticle_10"/>
        
        <span class="third-article-divide"/><p>Revenue at biotech arm Genzyme rose 20.5 percent, with a 134 percent rise in proceeds from multiple sclerosis treatment Lemtrada. Diabetes sales fell 4.5 percent, reflecting the trend of weaker revenue from blockbuster Lantus in the United States.</p><span id="midArticle_11"/><p>Sanofi's "main diabetes franchise remains in flux, with the company lowering estimates twice for this business over the last 18 months", Bernstein analyst Tim Anderson said in a note.</p><span id="midArticle_12"/><p>"(Sanofi's) research and development track record is not great, and it is guiding for no meaningful earnings per share growth in 2016/2017," said Anderson, who downgraded the stock to market-perform in November.</p><span id="midArticle_13"/><span id="midArticle_14"/><p> (Editing by James Regan and David Clarke)</p><span id="midArticle_15"/></div>
<br>[ad_2]
<br><a href="http://feeds.reuters.com/~r/reuters/topNews/~3/DxudX35DKoY/us-sanofi-results-idUSKCN0XQ0C8">Source </a>